Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
Abstract We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a cl...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infectious Diseases 2019-02, Vol.6 (2), p.ofz028-ofz028 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | ofz028 |
|---|---|
| container_issue | 2 |
| container_start_page | ofz028 |
| container_title | Open Forum Infectious Diseases |
| container_volume | 6 |
| creator | Bryson-Cahn, Chloe Beieler, Alison M Chan, Jeannie D Harrington, Robert D Dhanireddy, Shireesha |
| description | Abstract
We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure. |
| doi_str_mv | 10.1093/ofid/ofz028 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6388764</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A689479243</galeid><oup_id>10.1093/ofid/ofz028</oup_id><sourcerecordid>A689479243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-2a0c23454808809a409d7521f4f78e50a8a312771bec251e8da4e07109baa08e3</originalsourceid><addsrcrecordid>eNp9UU1r3DAQFaWlCUlOvRefSqFsoi-v5EshpF-BQANJehVjeZxV0UqubAe2v76zOA3ppQg00sx7j5l5jL0R_FTwRp3lPnR0_ebSvmCHUkm7sk1tXj57H7CTcfzJOReC19w0r9mB4lZZKetDNnyC2MIDJB9SBWN1gz6nDsquut1ggWFX9blQtoQ8U3WCYbOL2Wfv6QtzQQqXqUc_hZzGai9S_ZhjIm4bsbqGKWCaqus8zBH2mGP2qoc44sljPGJ3Xz7fXnxbXX3_enlxfrXy2jTTSgL3UulaW24tb0DzpjO1FL3ujcWagwUlpDGiRS9rgbYDjdzQTloAblEdsY-L7jC3W-w8dVEguqGELU3nMgT3byWFjbvPD26trDVrTQLvHwVK_jXjOLltGD3GCAlpF04Ka2ur19oQ9HSB3kNEF1KfSdHT6XAbaJ_YB8qfr21Ds0mtiPBhIfiSx7Fg_9SX4G7vq9v76hZfCf32-ShP2L8uEuDdAsjz8F-lP7BEroE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2188584647</pqid></control><display><type>article</type><title>Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population</title><source>Oxford Journals Open Access Collection</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Bryson-Cahn, Chloe ; Beieler, Alison M ; Chan, Jeannie D ; Harrington, Robert D ; Dhanireddy, Shireesha</creator><creatorcontrib>Bryson-Cahn, Chloe ; Beieler, Alison M ; Chan, Jeannie D ; Harrington, Robert D ; Dhanireddy, Shireesha</creatorcontrib><description>Abstract
We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofz028</identifier><identifier>PMID: 30838225</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Brief Report ; Care and treatment ; Dalbavancin ; Diseases ; Endocarditis ; Health aspects ; Methicillin ; Staphylococcus aureus ; Staphylococcus aureus infections</subject><ispartof>Open Forum Infectious Diseases, 2019-02, Vol.6 (2), p.ofz028-ofz028</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2019</rights><rights>COPYRIGHT 2019 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-2a0c23454808809a409d7521f4f78e50a8a312771bec251e8da4e07109baa08e3</citedby><cites>FETCH-LOGICAL-c479t-2a0c23454808809a409d7521f4f78e50a8a312771bec251e8da4e07109baa08e3</cites><orcidid>0000-0003-0246-4012 ; 0000-0002-6296-4011 ; 0000-0002-9411-699X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388764/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388764/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1598,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30838225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bryson-Cahn, Chloe</creatorcontrib><creatorcontrib>Beieler, Alison M</creatorcontrib><creatorcontrib>Chan, Jeannie D</creatorcontrib><creatorcontrib>Harrington, Robert D</creatorcontrib><creatorcontrib>Dhanireddy, Shireesha</creatorcontrib><title>Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population</title><title>Open Forum Infectious Diseases</title><addtitle>Open Forum Infect Dis</addtitle><description>Abstract
We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.</description><subject>Brief Report</subject><subject>Care and treatment</subject><subject>Dalbavancin</subject><subject>Diseases</subject><subject>Endocarditis</subject><subject>Health aspects</subject><subject>Methicillin</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus infections</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9UU1r3DAQFaWlCUlOvRefSqFsoi-v5EshpF-BQANJehVjeZxV0UqubAe2v76zOA3ppQg00sx7j5l5jL0R_FTwRp3lPnR0_ebSvmCHUkm7sk1tXj57H7CTcfzJOReC19w0r9mB4lZZKetDNnyC2MIDJB9SBWN1gz6nDsquut1ggWFX9blQtoQ8U3WCYbOL2Wfv6QtzQQqXqUc_hZzGai9S_ZhjIm4bsbqGKWCaqus8zBH2mGP2qoc44sljPGJ3Xz7fXnxbXX3_enlxfrXy2jTTSgL3UulaW24tb0DzpjO1FL3ujcWagwUlpDGiRS9rgbYDjdzQTloAblEdsY-L7jC3W-w8dVEguqGELU3nMgT3byWFjbvPD26trDVrTQLvHwVK_jXjOLltGD3GCAlpF04Ka2ur19oQ9HSB3kNEF1KfSdHT6XAbaJ_YB8qfr21Ds0mtiPBhIfiSx7Fg_9SX4G7vq9v76hZfCf32-ShP2L8uEuDdAsjz8F-lP7BEroE</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Bryson-Cahn, Chloe</creator><creator>Beieler, Alison M</creator><creator>Chan, Jeannie D</creator><creator>Harrington, Robert D</creator><creator>Dhanireddy, Shireesha</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0246-4012</orcidid><orcidid>https://orcid.org/0000-0002-6296-4011</orcidid><orcidid>https://orcid.org/0000-0002-9411-699X</orcidid></search><sort><creationdate>20190201</creationdate><title>Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population</title><author>Bryson-Cahn, Chloe ; Beieler, Alison M ; Chan, Jeannie D ; Harrington, Robert D ; Dhanireddy, Shireesha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-2a0c23454808809a409d7521f4f78e50a8a312771bec251e8da4e07109baa08e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Brief Report</topic><topic>Care and treatment</topic><topic>Dalbavancin</topic><topic>Diseases</topic><topic>Endocarditis</topic><topic>Health aspects</topic><topic>Methicillin</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bryson-Cahn, Chloe</creatorcontrib><creatorcontrib>Beieler, Alison M</creatorcontrib><creatorcontrib>Chan, Jeannie D</creatorcontrib><creatorcontrib>Harrington, Robert D</creatorcontrib><creatorcontrib>Dhanireddy, Shireesha</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open Forum Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bryson-Cahn, Chloe</au><au>Beieler, Alison M</au><au>Chan, Jeannie D</au><au>Harrington, Robert D</au><au>Dhanireddy, Shireesha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population</atitle><jtitle>Open Forum Infectious Diseases</jtitle><addtitle>Open Forum Infect Dis</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>6</volume><issue>2</issue><spage>ofz028</spage><epage>ofz028</epage><pages>ofz028-ofz028</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract
We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>30838225</pmid><doi>10.1093/ofid/ofz028</doi><orcidid>https://orcid.org/0000-0003-0246-4012</orcidid><orcidid>https://orcid.org/0000-0002-6296-4011</orcidid><orcidid>https://orcid.org/0000-0002-9411-699X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2328-8957 |
| ispartof | Open Forum Infectious Diseases, 2019-02, Vol.6 (2), p.ofz028-ofz028 |
| issn | 2328-8957 2328-8957 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6388764 |
| source | Oxford Journals Open Access Collection; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Brief Report Care and treatment Dalbavancin Diseases Endocarditis Health aspects Methicillin Staphylococcus aureus Staphylococcus aureus infections |
| title | Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T01%3A01%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dalbavancin%20as%20Secondary%20Therapy%20for%20Serious%20Staphylococcus%20aureus%20Infections%20in%20a%20Vulnerable%20Patient%20Population&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.au=Bryson-Cahn,%20Chloe&rft.date=2019-02-01&rft.volume=6&rft.issue=2&rft.spage=ofz028&rft.epage=ofz028&rft.pages=ofz028-ofz028&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofz028&rft_dat=%3Cgale_pubme%3EA689479243%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2188584647&rft_id=info:pmid/30838225&rft_galeid=A689479243&rft_oup_id=10.1093/ofid/ofz028&rfr_iscdi=true |